ESPR 241220 2.50P (ESPR241220P2500) Stock Options, News & Quotes

US OptionsDetailed Quotes

ESPR241220P2500

Watchlist

0.28
-0.12-30.00%

15min DelayClose Nov 21 15:59 ET

0.30High0.25Low

Intraday

5D
Daily

News

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
GlobeNewswireNov 21 08:00 ET
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Moomoo NewsNov 19 06:31 ET · Ratings
Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who...
BenzingaNov 18 10:31 ET
US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswireNov 8 16:15 ET
Express News | Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersNov 8 16:15 ET

Comments

MoMa Doge

6 hours ago

Slow but steady😉

$Esperion Therapeutics (ESPR.US)$ need to increase my holding for a decent Xmas meal….maybe next year

Ryo3830

Nov 19 16:45

Is a beautiful day 🌞😊

Nvidia's stock hit a new high on the first trading day post-Q3 earnings!

DazzlerAus

Nov 19 09:19

$ESPR 250117 2.00C$

Jaguar8

Nov 18 09:31

NEWS

$Esperion Therapeutics (ESPR.US)$
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
Esperion (ESPR) presented new exploratory data from the CLEAR Outcomes trial at the 2024 AHA Scientific Sessions, highlighting significant benefits of NEXLETOL (bempedoic acid).
The analysis showed patients with Peripheral Artery Disease (PAD) tak...

10xStockPicks

Nov 15 08:23

ESPR Will Propel Higher, Events This Weekend & Analyst Event Next Week, Stock Price

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...

+18